Major Pathological Response After Neoadjuvant Immunotherapy in Esophageal Spindle Cell Carcinoma: A Case Report

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2021 Feb 23

PMID 33619875

Citations 2

Authors

Yang Fu

Pei-Pei Wang

Du He

Yue Zheng

Zhen-Yu Ding

Affiliations

Soon will be listed here.

Abstract

Esophageal spindle cell carcinoma (ESpCC) is a rare subtype of esophageal carcinoma, accounting for 1% of all esophageal malignancies. The clinical outcome is unknown due to the lack of treatment options. Here, we present the case of a 60-year-old male with initially unresectable ESpCC, in which platinum-based concurrent chemoradiotherapy was unsuccessful. He was subsequently treated with neoadjuvant immunotherapy and after surgery achieved a complete pathological response; therefore, neoadjuvant immunotherapy might be a novel option for ESpCC patients.

Citing Articles

Primary maxillary sinus carcinosarcoma with multidisciplinary management: a case report with 4 years follow-up and literature review.

Li J, Wang S, Tang X, Que L, Han W, Yu B BMC Oral Health. 2023; 23(1):96.

PMID: 36788533 PMC: 9926723. DOI: 10.1186/s12903-022-02604-5.

Major pathological response after neoadjuvant immunotherapy in esophageal spindle cell carcinoma: A case report.

Fu Y, Wang P, He D, Zheng Y, Ding Z Thorac Cancer. 2021; 12(8):1234-1239.

PMID: 33619875 PMC: 8046125. DOI: 10.1111/1759-7714.13905.

References

Guarino M, Tricomi P, Giordano F, Cristofori E . Sarcomatoid carcinomas: pathological and histopathogenetic considerations. Pathology. 1996; 28(4):298-305. DOI: 10.1080/00313029600169224. View

Sanada Y, Hihara J, Yoshida K, Yamaguchi Y . Esophageal carcinosarcoma with intramural metastasis. Dis Esophagus. 2006; 19(2):119-31. DOI: 10.1111/j.1442-2050.2006.00551.x. View

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K . Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020; 21(10):1353-1365. DOI: 10.1016/S1470-2045(20)30445-9. View

Kojima T, Shah M, Muro K, Francois E, Adenis A, Hsu C . Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin Oncol. 2020; 38(35):4138-4148. DOI: 10.1200/JCO.20.01888. View

Burmeister B, Smithers B, Gebski V, Fitzgerald L, Simes R, Devitt P . Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005; 6(9):659-68. DOI: 10.1016/S1470-2045(05)70288-6. View

Raza M, Mazzara P . Sarcomatoid carcinoma of esophagus. Arch Pathol Lab Med. 2011; 135(7):945-8. DOI: 10.5858/2010-0074-RSR.1. View

Kato K, Cho B, Takahashi M, Okada M, Lin C, Chin K . Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20(11):1506-1517. DOI: 10.1016/S1470-2045(19)30626-6. View

Hanif A, Pandey M, Khan S, Attwood K, George S . Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitors. Oncoimmunology. 2019; 8(8):1606639. PMC: 6682356. DOI: 10.1080/2162402X.2019.1606639. View

Kwon M, Hong S, Cho H, Ahn G, Lee S, Lee K . Extensive and divergent chromosomal losses in squamous and spindle-cell components of esophageal sarcomatoid carcinoma. Virchows Arch. 2003; 443(5):635-42. DOI: 10.1007/s00428-003-0873-4. View

10.

Wang L, Lin Y, Long H, Liu H, Rao H, He Y . Esophageal carcinosarcoma: a unique entity with better prognosis. Ann Surg Oncol. 2012; 20(3):997-1004. DOI: 10.1245/s10434-012-2658-y. View

11.

Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z . Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol. 2018; 36(27):2796-2803. PMC: 6145832. DOI: 10.1200/JCO.2018.79.1483. View

12.

Zhang B, Xiao Q, Yang D, Li X, Hu J, Wang Y . Spindle cell carcinoma of the esophagus: A multicenter analysis in comparison with typical squamous cell carcinoma. Medicine (Baltimore). 2016; 95(37):e4768. PMC: 5402570. DOI: 10.1097/MD.0000000000004768. View

13.

Shapiro J, van Lanschot J, Hulshof M, van Hagen P, van Berge Henegouwen M, Wijnhoven B . Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015; 16(9):1090-1098. DOI: 10.1016/S1470-2045(15)00040-6. View

14.

Mok T, Wu Y, Kudaba I, Kowalski D, Cho B, Turna H . Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019; 393(10183):1819-1830. DOI: 10.1016/S0140-6736(18)32409-7. View

15.

Schrock A, Li S, Frampton G, Suh J, Braun E, Mehra R . Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. J Thorac Oncol. 2017; 12(6):932-942. DOI: 10.1016/j.jtho.2017.03.005. View

16.

Mayenga M, Assie J, Monnet I, Massiani M, Tabeze L, Friard S . Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases. Lung Cancer. 2020; 150:21-25. DOI: 10.1016/j.lungcan.2020.09.008. View

17.

Iwaya T, Maesawa C, Tamura G, Sato N, Ikeda K, Sasaki A . Esophageal carcinosarcoma: a genetic analysis. Gastroenterology. 1997; 113(3):973-7. DOI: 10.1016/s0016-5085(97)70194-x. View

18.

Domblides C, Leroy K, Monnet I, Mazieres J, Barlesi F, Gounant V . Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma. J Thorac Oncol. 2020; 15(5):860-866. DOI: 10.1016/j.jtho.2020.01.014. View

19.

Gounant V, Brosseau S, Naltet C, Opsomer M, Antoine M, Danel C . Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma. Lung Cancer. 2016; 99:162-5. DOI: 10.1016/j.lungcan.2016.07.010. View

20.

Debien V, Thouvenin J, Lindner V, Barthelemy P, Lang H, Flippot R . Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities. Cancers (Basel). 2020; 12(1). PMC: 7016737. DOI: 10.3390/cancers12010099. View